Bayer and J&J last year showed their legacy blood thinner Xarelto could help post-surgery patients in tough-to-treat artery disease. Now, the partners have data showing those benefits extend far beyond initial vascular complications.
May 16, 2021
Compared with valsartan alone, the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan (Entresto; Novartis) reduces triglycerides among patients with heart failure and preserved ejection fraction (HFpEF), according to results from a PARAGON-HF subanalysis. The effect was particularly marked in patients with higher triglycerides at baseline.
“Our research adds to the growing literature of the favorable metabolic effects of sacubitril/valsartan,” Senthil Selvaraj, MD (Hospital of the University of Pennsylvania, Philadelphia), who presented the findings today at the American College of Cardiology 2021 Scientific Session, told TCTMD in an email. “Sacubitril/valsartan may be part of the therapeutic armamentarium is reducing triglycerides as adjunct therapy. However, outcomes studies looking at related cardiovascular endpoints in high-risk populations are needed.”
LAA Occlusion During Surgery Cuts Stroke Risk medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.